BioCardia Advances Clinical Trials Amid Financial Challenges

Biocardia ( (BCDA) ) has released its Q2 earnings. Here is a breakdown of the information Biocardia presented to its investors.

BioCardia, Inc., headquartered in Sunnyvale, California, is a biotechnology company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with a unique emphasis on its CardiAMP and CardiALLO cell therapy platforms.

In its second-quarter 2025 earnings report, BioCardia highlighted significant progress in its clinical trials and strategic initiatives, despite reporting a net loss. The company is advancing its CardiAMP and CardiALLO therapies and has strengthened its intellectual property portfolio with a new patent.

Key financial metrics for the quarter include an increase in research and development expenses to $1.4 million, driven by the CardiAMP HF Trial activities, and a net loss of $2.0 million, up from $1.6 million in the same period last year. BioCardia’s cash balance stood at approximately $980,000 at the end of June 2025, with additional funds raised through stock sales. The company is also preparing for regulatory submissions in Japan and the U.S. for its CardiAMP system and Helix delivery platform.

BioCardia’s ongoing clinical trials, including the CardiAMP HF II in the U.S. and the CardiALLO Phase 1/2 trial, are crucial to its strategy. The company is also seeking regulatory approvals and exploring nondilutive funding opportunities to support its growth and development plans.

Looking ahead, BioCardia is focused on achieving several milestones, including regulatory reviews and trial enrollments, which could significantly impact its market presence and financial performance. The management remains optimistic about the potential transformative impact of its therapies on patients and stakeholders.